Market revenue in 2023 | USD 42.8 million |
Market revenue in 2030 | USD 100.6 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Ctms |
Fastest growing segment | ECOA |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | ECOA, EDC & CDMS, Clinical Analytics Platforms, Clinical Data Integration Platforms, Safety solutions, CTMS, RTSM, ETMF, EConsent |
Key market players worldwide | DATATRAK International Inc, Oracle Corp, PAREXEL, Dassault Systemes SE, Signant Health, Clario, eClinicalWorks, International Business Machines Corp, IQVIA Holdings Inc, Veeva Systems Inc Class A, Anju Software, MaxisIT Inc., Castor |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to eclinical solutions market will help companies and investors design strategic landscapes.
Ctms was the largest segment with a revenue share of 18.69% in 2023. Horizon Databook has segmented the Egypt eclinical solutions market based on ecoa, edc & cdms, clinical analytics platforms, clinical data integration platforms, safety solutions, ctms, rtsm, etmf, econsent covering the revenue growth of each sub-segment from 2018 to 2030.
There has been considerable shift in conducting clinical trials by Transitional Pharmaceutical Companies (TNC) in low- and middle-income countries over the last two decades. Presence of favorable research environment and low cost of conducting clinical trials marks are making Egypt an attractive location for medicine testing.
Egypt is the second most popular country after South Africa for conducting clinical trials for the TNCs. There has been a steady increase in the number of clinical trials being conducted in Egypt. As of February 2016, 57 drug trials were active in Egypt. Almost half of these trials were being conducted by F. Hoffmann-La Roche Ltd and Novartis AG. The clinical trial regulatory authorities in this country allow foreign drug trials to be conducted in Egypt only when the product has received an approval in the originating country.
Horizon Databook provides a detailed overview of country-level data and insights on the Egypt eclinical solutions market , including forecasts for subscribers. This country databook contains high-level insights into Egypt eclinical solutions market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account